Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Chugai
Pharma
Takeda, Innovent-Lilly, Roche—Fierce Pharma Asia
Takeda made pipeline cuts in Q3. Innovent reported a head-to-head win against semaglutide. Roche inked a respiratory bispecific deal. And more.
Angus Liu
Oct 31, 2025 8:20am
Chugai strikes $200M deal for IgAN asset in Asian countries
Oct 24, 2025 9:40am
Licensing deals, Nkarta CEO comments and more—Fierce Pharma Asia
Oct 24, 2025 8:30am
Lilly-Innovent, Dizal, bispecific ADC—Fierce Pharma Asia
Jul 10, 2025 5:20pm
A $410M obesity debut, Legend, BeiGene and more—Fierce Pharma Asia
Jan 10, 2025 9:00am
Gilead leads Asian patient groups' drugmaker reputation rankings
Sep 25, 2024 10:40am
